Scaling Cell Therapies: Auto vs. Allo
To achieve commercial success, a developed process must be scalable and suitable for a manufacturing environment. The scaling strategy depends on the type of cell therapy.
Now available On-Demand from Cell & Gene Live - a deep dive into why collaboration between process development and manufacturing leads to accelerated timelines, lowered costs, and improved risk assessment for both autologous and allogeneic cell therapies. Michael Blackton, SVP Cell Therapy Manufacturing at Nurix Therapeutics and John Lee, VP Head of Cell Therapy at Center for Breakthrough Medicines share their expertise from the biopharma and CDMO points of view, respectively.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.